IsoRay (ISR) Gets a Hold Rating from Dawson James

Dawson James analyst Jason Kolbert maintained a Hold rating on IsoRay (ISRResearch Report) on November 11. The company’s shares closed last Tuesday at $0.40, close to its 52-week low of $0.40.

According to TipRanks.com, Kolbert has 0 stars on 0-5 stars ranking scale with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for IsoRay.

See the top stocks recommended by analysts >>

IsoRay’s market cap is currently $56.92M and has a P/E ratio of -10.08.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Read More on ISR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed